Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use

Sophie Thoo; Sudha Cugati; Andrew Lee; Celia Chen

doi:10.1177/1352458514528759

Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use

Mult Scler. 2015 Feb;21(2):249-51. doi: 10.1177/1352458514528759. Epub 2014 Apr 2.

Authors

Sophie Thoo¹, Sudha Cugati¹, Andrew Lee², Celia Chen³

Affiliations

¹ Department of Ophthalmology and the Division of Medicine, Flinders University, Australia.
² Flinders Medical Centre and Flinders University, Australia.
³ Department of Ophthalmology, Flinders Medical Centre and Flinders University, Flinders Drive, Bedford Park, SA 5042 Australia Celia.Chen@health.sa.gov.au.

PMID: 24696055
DOI: 10.1177/1352458514528759

Abstract

The occurrence of macular edema as an adverse effect of fingolimod is well documented. Treatment modalities used to manage fingolimod-associated macular edema (FAME) have included nonsteroidal anti-inflammatory agents and sub-tenon injection. We describe two cases where intravitreal injection is used to successfully treat FAME in patients who were previously unsuccessfully treated with topical nonsteroidal anti-inflammatories.

Keywords: Fingolimod; edema; multiple sclerosis; steroid.

Publication types

Case Reports

MeSH terms

Aged
Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / pharmacology*
Female
Fingolimod Hydrochloride / administration & dosage
Fingolimod Hydrochloride / adverse effects*
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects*
Macular Edema / chemically induced*
Macular Edema / drug therapy*
Middle Aged
Multiple Sclerosis / drug therapy*
Triamcinolone / administration & dosage
Triamcinolone / pharmacology*

Substances

Anti-Inflammatory Agents
Immunosuppressive Agents
Triamcinolone
Fingolimod Hydrochloride